Zepbound vs Wegovy

Zepbound (tirzepatide) was reviewed for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity or overweight. The FDA review for Zepbound noted a difference from placebo in AHI (LS Mean) of -23.8 and a percent change from baseline in AHI of -56.2.

Wegovy (semaglutide) was reviewed for chronic weight management and to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. The EMA EPAR variation assessment report for Wegovy indicated that 88.47% of participants achieved a body weight reduction of ≥5%, and the estimated treatment difference in body weight change versus placebo was -14.81.

These drugs were studied in separate trials with different designs, populations, and timepoints. Their respective trials focused on distinct primary endpoints, involved different patient populations, and utilized different comparator arms. The figures presented are from each drug's own review documents and are not head-to-head comparisons; therefore, neither drug is presented as superior to the other.